KC
DCOY

Kepos Capital’s Decoy Therapeutics DCOY Stock Holding History

Kepos Capital’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15
Closed -$218K – 559
2022
Q1 		$218K Hold
15
– – 0.02% 316
2021
Q4 		$272K Hold
15
– – 0.02% 366
2021
Q3 		$559K Hold
15
– – 0.04% 347
2021
Q2 		$581K Hold
15
– – 0.04% 300
2021
Q1 		$811K Buy
15
+12
+400% +$688K 0.05% 292
2020
Q4 		$114K Hold
3
– – 0.01% 311
2020
Q3 		$105K Buy
+3
New +$119K 0.01% 242

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Kepos Capital's DCOY Position: Q2 2022 in Review

Kepos Capital sold out of Decoy Therapeutics (DCOY) in Q2 2022, closing a stake of 15 shares — an estimated $218K sold.

Kepos Capital first reported a position in DCOY in Q3 2020 and held it in 7 quarters. The position peaked at $811K in Q1 2021. 19 funds tracked by Wall St. Rank hold DCOY as of Q2 2022.

  • Kepos Capital reported no remaining Decoy Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kepos Capital sold 15 Decoy Therapeutics shares in Q2 2022, an estimated $218K.
  • Kepos Capital first reported a position in Decoy Therapeutics in Q3 2020 and held it in 7 quarters.
  • Kepos Capital's Decoy Therapeutics position peaked at $811K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2022.

Based on Kepos Capital's 13F filing for Q2 2022, filed 12 Aug 2022.